Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries

The ovarian epithelial cells carrying heterozygous BRCA1 or BRCA2 mutation (we called BRCA1/2 mutation) are known to predispose to the development of ovarian cancer; however, the molecular basis of such predisposition is largely unknown. We hypothesize that BTAK may be a potential target for heterozygous BRCA1/2 mutation. We sought to determine the relationship between the status of BRCA1/2 heterozygous mutation and BTAK expression in prophylactically removed ovaries as compared with normal ovaries and ovarian cancer controls. Western blot analysis of BTAK was performed in a primary cell culture carrying heterozygous BRCA1 mutation and three normal ovarian surface epithelial cell cultures. Immunohistochemical analysis of BTAK expression was also performed by image analysis in ovaries of 21 patients with known BRCA1/2 mutation or very strong family history of breast/ovarian cancer that underwent prophylactic oophorectomy, 38 normal ovaries from patients without any known mutation, and 194 ovarian carcinomas. The BTAK expression was significantly increased in primary culture carrying a heterozygous BRCA1 mutation as compared to those with no known BRCA1/2 mutation. Immunohistochemical staining of BTAK showed increased expression in ovarian epithelial cells carrying BRCA1/2 mutation or strong breast/ovarian family history compared with normal ovaries (P<0.001). Higher BTAK expression was found in ovarian cancer cells compared to ovaries without cancer but with known BRCA1/2 mutation or strong family history (P<0.001), and expression levels of BTAK and p53 were directly correlated (r=0.306; P<0.001). Increased expression of BTAK is directly correlated with mutation status of BRCA1/2 genes, suggesting that mutation in a single allele of either BRCA1 or 2 may be responsible for the activation of BTAK. This activation may be a key early genetic event in the development of hereditary ovarian cancer.

[1]  A. D’Andrea,et al.  The Fanconi Anemia/BRCA pathway: new faces in the crowd. , 2005, Genes & development.

[2]  D Lowe,et al.  Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Journal of the National Cancer Institute.

[3]  R. Ozols,et al.  Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. , 2006, Gynecologic oncology.

[4]  J Gil,et al.  Ovarian dysplasia in prophylactic oophorectomy specimens , 1999, Cancer.

[5]  D. Medina,et al.  Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. , 2002, Cancer research.

[6]  D. F. Easton,et al.  The genetics of breast and ovarian cancer. , 1995, British Journal of Cancer.

[7]  A. Godwin,et al.  Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. , 1996, Journal of the National Cancer Institute.

[8]  C. Deng,et al.  Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation , 2006, Oncogene.

[9]  S. Sen,et al.  Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. , 2005, Oncology research.

[10]  G. Mills,et al.  Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma , 2006, Cancer.

[11]  P. Meltzer,et al.  Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Nigam H. Shah,et al.  Can we identify cellular pathways implicated in cancer using gene expression data? , 2003, Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE Bioinformatics Conference. CSB2003.

[13]  C. Voelkel-Johnson An Antibody Against DR4 (TRAIL-R1) in Combination with Doxorubicin Selectively Kills Malignant but not Normal Prostate Cells , 2003, Cancer biology & therapy.

[14]  R. Ozols,et al.  Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies , 2003, Cancer.

[15]  A. Venkitaraman,et al.  Abnormal Cytokinesis in Cells Deficient in the Breast Cancer Susceptibility Protein BRCA2 , 2004, Science.

[16]  T. Ouchi,et al.  Cell Cycle Differences in DNA Damage-induced BRCA1 Phosphorylation Affect Its Subcellular Localization* , 2003, The Journal of Biological Chemistry.

[17]  H. Lynch,et al.  Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. , 2000, Gynecologic oncology.

[18]  A. Godwin,et al.  Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer , 1996, International journal of cancer.

[19]  C. Prigent,et al.  Aurora kinases, aneuploidy and cancer, a coincidence or a real link? , 2005, Trends in cell biology.

[20]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[21]  Domenico Coppola,et al.  Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  K. Offit,et al.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.

[23]  R. Bast,et al.  Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. , 2006, Methods in enzymology.

[24]  H. Saya,et al.  Roles of aurora‐A kinase in mitotic entry and G2 checkpoint in mammalian cells , 2002, Genes to cells : devoted to molecular & cellular mechanisms.

[25]  D. V. Von Hoff,et al.  Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. , 2003, Molecular cancer therapeutics.

[26]  Y. Nakamura,et al.  Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation , 2001, British Journal of Cancer.

[27]  J. Niloff,et al.  Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Kastan,et al.  p53 and ATM: cell cycle, cell death, and cancer. , 1997, Advances in cancer research.

[29]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[30]  W. El-Deiry,et al.  Repression of BRCA1 through a Feedback Loop Involving p53* , 2000, The Journal of Biological Chemistry.

[31]  F. Penault-Llorca,et al.  Prophylactic oophorectomy , 2003, Cancer.

[32]  B. Rosen,et al.  Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.

[33]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[34]  S. Sen,et al.  Dynamic association of a tumor amplified kinase, Aurora-A, with the centrosome and mitotic spindle. , 2003, Cell motility and the cytoskeleton.

[35]  H. Saya,et al.  RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. , 2005, Cancer research.

[36]  P. Kruk,et al.  Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. , 1999, Gynecologic oncology.

[37]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[38]  H. Saya,et al.  Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human Cells , 2003, Cell.

[39]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[40]  Hiroshi Katayama,et al.  The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.

[41]  B. Weber,et al.  BRCA1 signals ARF-dependent stabilization and coactivation of p53 , 1999, Oncogene.

[42]  S. Sen,et al.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines , 1997, Oncogene.

[43]  Qing‐Yu He,et al.  Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies. , 2005, Gynecologic oncology.

[44]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[45]  B. Werness,et al.  Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. , 1999, Human pathology.

[46]  J. Swedlow,et al.  Mitotic mechanics: the auroras come into view. , 2003, Current opinion in cell biology.

[47]  Erich A Nigg,et al.  Aurora kinases link chromosome segregation and cell division to cancer susceptibility. , 2004, Current opinion in genetics & development.

[48]  D. Bell,et al.  Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.

[49]  N. Shao,et al.  The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter , 1999, Oncogene.

[50]  P. V. van Diest,et al.  Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition , 2003, Histopathology.

[51]  L. Hsu,et al.  Identification of a -Tubulin-binding Domain in BRCA11 , 2001 .

[52]  R. White,et al.  Identification of a gamma-tubulin-binding domain in BRCA1. , 2001, Cancer research.